Embecta plunges 58% as shareholder lawsuit alleges misleading guidance

Embecta Corp. shares lost 58% of their value on May 5 after the insulin needle maker missed quarterly expectations and cut its full-year forecast.

"The company continuously reaffirmed guidance and touted its pen needle segment as 'incredibly resolute' while failing to consider the impact of patients not on payer plans," plaintiff Harrison Apitz-Grossman said in the complaint filed June 17 in the US District Court for the District of New Jersey.

The Parsippany, New Jersey-based company reported Q2 2026 revenue that declined more than 14%, far exceeding the guidance range of flat to a 2% decline. Embecta also lowered its full-year 2026 guidance, citing weakness in US pen needle sales. The stock closed at $3.90 on May 5, down from $9.25 the prior session.

The class action seeks to represent investors who purchased Embecta shares between Nov. 25, 2025 and May 4, 2026. The lead plaintiff deadline is Aug. 17. At least three law firms — Schall Law Firm, Gross Law Firm and HBSS — have announced investigations into whether the company issued false or misleading statements about demand for its insulin pen needles.

The lawsuit alleges Embecta knew or recklessly disregarded that its guidance was unattainable while presenting an overwhelmingly positive outlook to investors. The company had described its pen needle business as "incredibly resolute" just weeks before the disappointing results.

Embecta spun off from Becton Dickinson & Co. in 2022 and derives the bulk of its revenue from disposable pen needles used with insulin delivery devices. The complaint contends the company failed to disclose competitive threats to that core business, including the impact of patients shifting to lower-cost alternatives.

The 58% single-day decline erased roughly $1.4 billion in market value based on the company's pre-selloff market capitalization of about $2.4 billion. Embecta shares have continued to trade near the post-earnings lows, reflecting persistent uncertainty about the company's growth trajectory.

The Schall Law Firm, which is also investigating, said the investigation focuses on whether the company issued false or misleading statements and failed to disclose information pertinent to investors.

The lawsuit puts Embecta's core business strategy under scrutiny and raises questions about management's credibility with investors. The Aug. 17 lead plaintiff deadline will determine whether the case proceeds as a consolidated class action.

This article is for informational purposes only and does not constitute investment advice.